Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Netherlands Cancer Institute
With
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological proof of metastatic NSCLC; for PART B: treated with first line therapy for metastatic disease only.
Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA wild-type (exon 9 and 20)
Age ≥ 18 years
Able and willing to give written informed consent
WHO performance status of 0 or 1 (part A and B)
You may not be if
Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment.
History of another primary malignancy
Symptomatic or untreated leptomeningeal disease
Symptomatic brain metastasis
History of interstitial lung disease or pneumonitis
Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients
Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), or a history of uveitis, retinal vein occlusion, central serous retinopathy, or retinal detachment
Patients with left ventricular ejection fraction (LVEF) \< 50%
Clareo Health | Lapatinib Plus Trametinib in KRAS Mutant NSCLC
